Welcome to industryreportstore.com

Need help? +44(0)20 7936 6830

Parkinson's Disease market research, reports and industry analysis

mail

Contact us for professional industry advice

Email us or call

+44(0)20 7936 6830
mail

for FREE research alerts
to your inbox

23 Item(s)

Page 1 of 3

  1. Global Parkinson's Disease Partnering 2010 to 2016

    By: Current Partnering
    , Published: Mar-2016
    , Product code: CP2203par
    Provides understanding and access to the parkinson's disease partnering deals and agreements entered into by the worlds leading healthcare companies.
    $1,495.00

  2. Parkinson’s Disease Therapeutics in Major Developed Markets to 2021: Early Pipeline Shifts Towards Disease-Modifying Therapies, while Short Term Growth Driven by Long-Acting Symptomatic Treatments

    By: GBI Research
    , Published: Feb-2016
    , Product code: GBIHC401MR
    Parkinson's Disease (PD) is a progressive, chronic neurodegenerative condition, which is currently incurable. It is associated with old age, and characterized by the loss of neurons in the substantia nigra region of the brain. The global Parkinson's Disease (PD) prevalence was estimated at 16.1 million in 2011, and after Alzheimer's disease it is the second most common neurodegenerative disease worldwide.
    $4,995.00

  3. PharmaPoint: Parkinson’s Disease - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

    By: GlobalData
    , Published: Jun-2015
    , Product code: GDHC011EPIDR
    Parkinson’s disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinson’s disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly. It is expected that the prevalence of Parkinson’s disease in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan) and Brazil will increase from 3.2m people in 2012 to 4.3m people in 2022, driven by an aging population in all markets. Dopaminergic therapies have been fairly effective in treating bradykinesia, but several unmet needs remain. Some needs will be met during the forecast period from 2012-2022, while others, such as the need for disease-modifying drugs, will remain. GlobalData expects that advancements will be made in levodopa administration and that four new molecular entities will be introduced to the market by 2022, these factors along with increased patient numbers from an aging population will drive the market during the forecast period.
    $10,995.00

  4. Trends in Therapeutic Partnering

    By: Current Partnering
    , Published: Aug-2014
    , Product code: CP2290-
    Provides a detailed understanding and analysis of the 35 most popular therapeutic targets for partnering in the period 2009 to mid 2014
    $3,995.00

  5. Global Parkinson's Disease Market 2014-2018

    By: Technavio
    , Published: Jul-2014
    , Product code: IRTNTR3862
    About Parkinson’s Disease Parkinson’s disease is a progressive neurodegenerative disorder characterized by damage of dopaminergic neurons located in various parts of brain including the substantia nigra. This lowers the concentration of dopamine in the striatum. A decrease in dopamine levels by 80 percent leads to the development of symptoms associated with Parkinson’s disease such as tremor, bradykinesia, and muscular rigidity. It is usually diagnosed in the population aged 60 and over; however, earlier incidences have been reported. Based on the severity, it can be categorized into early stage, mid stage and late (or advanced) stage. Currently, the approved therapies provide only symptomatic relief. Levodopa is the standard drug for the treatment of Parkinson’s disease; however, it is associated with the incidence of dyskinesias. Alternative surgical procedures such as bilateral globus pallidus interna stimulation and bilateral subthalamic nucleus stimulation can be used in Parkinson’s disease patients under certain circumstances.
    $2,500.00

  6. PharmaPoint: Parkinson’s Disease - US Drug Forecast and Market Analysis to 2022

    By: GlobalData
    , Published: Mar-2014
    , Product code: GDHC235CFR-
    Parkinson’s disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinson’s disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly. Dopaminergic therapies have been fairly effective in treating bradykinesia, but several unmet needs remain. Some needs will be met during the forecast period from 2012-2022, while others, such as the need for disease-modifying drugs, will remain. GlobalData expects that advancements will be made in levodopa administration and that four new molecular entities will be introduced to the market by 2022, these factors along with increased patient numbers from an aging population will drive the market during the forecast period.
    $4,995.00

  7. PharmaPoint: Parkinson’s Disease - 5EU Drug Forecast and Market Analysis to 2022

    By: GlobalData
    , Published: Mar-2014
    , Product code: GDHC236CFR-
    Parkinson’s disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinson’s disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly. Dopaminergic therapies have been fairly effective in treating bradykinesia, but several unmet needs remain. Some needs will be met during the forecast period from 2012-2022, while others, such as the need for disease-modifying drugs, will remain. GlobalData expects that advancements will be made in levodopa administration and that four new molecular entities will be introduced to the market by 2022, these factors along with increased patient numbers from an aging population will drive the market during the forecast period.
    $6,995.00

  8. PharmaPoint: Parkinson’s Disease - Japan Drug Forecast and Market Analysis to 2022

    By: GlobalData
    , Published: Mar-2014
    , Product code: GDHC237CFR-
    Parkinson’s disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinson’s disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly. Dopaminergic therapies have been fairly effective in treating bradykinesia, but several unmet needs remain. Some needs will be met during the forecast period from 2012-2022, while others, such as the need for disease-modifying drugs, will remain. GlobalData expects that advancements will be made in levodopa administration and that four new molecular entities will be introduced to the market by 2022, these factors along with increased patient numbers from an aging population will drive the market during the forecast period.
    $4,995.00

  9. PharmaPoint: Parkinson’s Disease - Brazil Drug Forecast and Market Analysis to 2022

    By: GlobalData
    , Published: Mar-2014
    , Product code: GDHC238CFR-
    Parkinson’s disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinson’s disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly. Dopaminergic therapies have been fairly effective in treating bradykinesia, but several unmet needs remain. Some needs will be met during the forecast period from 2012-2022, while others, such as the need for disease-modifying drugs, will remain. GlobalData expects that advancements will be made in levodopa administration and that four new molecular entities will be introduced to the market by 2022, these factors along with increased patient numbers from an aging population will drive the market during the forecast period.
    $4,995.00

  10. Madopar (Parkinson’s Disease) - Forecast and Market Analysis to 2022

    By: GlobalData
    , Published: Mar-2014
    , Product code: GDHC389DFR-
    Parkinson’s disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinson’s disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly. Dopaminergic therapies have been fairly effective in treating bradykinesia, but several unmet needs remain. Some needs will be met during the forecast period from 2012-2022, while others, such as the need for disease-modifying drugs, will remain. GlobalData expects that advancements will be made in levodopa administration and that four new molecular entities will be introduced to the market by 2022, these factors along with increased patient numbers from an aging population will drive the market during the forecast period.
    $3,495.00

23 Item(s)

Page 1 of 3